We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

116 hedge funds and large institutions have $168M invested in VistaGen Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

9% more funds holding

Funds holding: 106 → 116 (+10)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.12% less ownership

Funds ownership: 2.31% → 2.18% (-0.12%)

19% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 37

38% less capital invested

Capital invested by funds: $269M → $168M (-$101M)

92% less call options, than puts

Call options by funds: $41K | Put options by funds: $487K

Holders
116
Holders Change
+10
Holders Change %
+9.43%
% of All Funds
1.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
30
Reduced
37
Closed
9
Calls
$41K
Puts
$487K
Net Calls
-$446K
Net Calls Change
+$520K

Top Buyers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
+$2.37M
2
Norges Bank
Norges Bank
Norway
+$1.92M
3
Millennium Management
Millennium Management
New York
+$1.79M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.71M
5
SFM
Sphera Funds Management
Israel
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$7.25M
2
LGM
Logos Global Management
California
-$1.45M
3
GTC
Ghost Tree Capital
New York
-$995K
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$956K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$856K
Name Holding Trade Value Shares
Change 		Change in
Stake
NAS
101
Nicolet Advisory Services
Wisconsin
$14K – – –
Mackenzie Financial
102
Mackenzie Financial
Ontario, Canada
$13K – – –
RJFSA
103
Raymond James Financial Services Advisors
Florida
$13K +$15.6K +358 New
DWM
104
Drive Wealth Management
Utah
$12K – – –
Prudential Financial
105
Prudential Financial
New Jersey
$12K – – –
ACM
106
Aquatic Capital Management
Illinois
$12K +$6.54K +150 +83%
AC
107
AlphaCore Capital
California
$12K +$14.5K +333 New
AWS
108
Atria Wealth Solutions
New York
$12K +$14.5K +333 New
Russell Investments Group
109
Russell Investments Group
United Kingdom
$10K – – –
Citigroup
110
Citigroup
New York
$9K -$589K -13,511 -98%
ETC
111
Exchange Traded Concepts
Oklahoma
$8K +$9.68K +222 New
CAPTRUST Financial Advisors
112
CAPTRUST Financial Advisors
North Carolina
$6K -$12K -275 -62%
IA
113
IFP Advisors
Florida
$5K +$4.97K +114 New
SWM
114
Spire Wealth Management
Virginia
$1K +$262 +6 +22%
Rafferty Asset Management
115
Rafferty Asset Management
New York
– -$956K -16,343 Closed
SCM
116
Silverarc Capital Management
Massachusetts
– -$827K -14,139 Closed
BWM
117
Bulltick Wealth Management
Florida
– -$436K -7,445 Closed
RCG
118
Rock Creek Group
District of Columbia
– -$263K -5,386 Closed
E
119
Ergoteles
New York
– -$201K -3,428 Closed
EFM
120
E Fund Management
China
– -$32K -540 Closed
Bank of Montreal
121
Bank of Montreal
Ontario, Canada
– -$30K -493 Closed
ZIM
122
Zacks Investment Management
Illinois
– -$23K -400 Closed
CWS
123
Confluence Wealth Services
Pennsylvania
– -$3K -57 Closed
Fidelity Investments
124
Fidelity Investments
Massachusetts
– +$392 +9 +64%
1 2 3 4
5

VTGN Hedge Fund Activity: Q1 2022 in Review

116 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2022, worth a combined $168M — down 38% from $269M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new VTGN positions and 9 closed out — a net gain of 10 holders — while 30 added to existing stakes and 37 trimmed.

The largest buyer was Commodore Capital, adding an estimated $2.37M. The largest seller was State Street, cutting an estimated $7.25M.

  • 116 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2022, up from 106 in Q4 2021.
  • Funds reported $168M of VistaGen Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
  • 19 funds opened new VistaGen Therapeutics positions in Q1 2022 and 9 closed out, a net change of +10 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $2.37M added.
  • The largest VistaGen Therapeutics seller in Q1 2022 was State Street, an estimated $7.25M sold.

Based on aggregated 13F filings for Q1 2022.